GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Seelos Therapeutics Inc (FRA:NXE0) » Definitions » Cyclically Adjusted PB Ratio

Seelos Therapeutics (FRA:NXE0) Cyclically Adjusted PB Ratio : 0.01 (As of Jun. 06, 2024)


View and export this data going back to . Start your Free Trial

What is Seelos Therapeutics Cyclically Adjusted PB Ratio?

As of today (2024-06-06), Seelos Therapeutics's current share price is €2.00. Seelos Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €246.20. Seelos Therapeutics's Cyclically Adjusted PB Ratio for today is 0.01.

The historical rank and industry rank for Seelos Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

FRA:NXE0' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.01   Med: 0.09   Max: 5.09
Current: 0.03

During the past years, Seelos Therapeutics's highest Cyclically Adjusted PB Ratio was 5.09. The lowest was 0.01. And the median was 0.09.

FRA:NXE0's Cyclically Adjusted PB Ratio is ranked better than
95.16% of 661 companies
in the Biotechnology industry
Industry Median: 1.75 vs FRA:NXE0: 0.03

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Seelos Therapeutics's adjusted book value per share data for the three months ended in Mar. 2024 was €-15.970. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €246.20 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Seelos Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Seelos Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Seelos Therapeutics Cyclically Adjusted PB Ratio Chart

Seelos Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.04 0.05 0.06 0.02

Seelos Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 0.14 0.03 0.02 0.11

Competitive Comparison of Seelos Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Seelos Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Seelos Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Seelos Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Seelos Therapeutics's Cyclically Adjusted PB Ratio falls into.



Seelos Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Seelos Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=2.00/246.2
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Seelos Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Seelos Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-15.97/131.7762*131.7762
=-15.970

Current CPI (Mar. 2024) = 131.7762.

Seelos Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201406 16,450.943 100.560 21,557.812
201409 16,623.214 100.428 21,812.127
201412 2,509.677 99.070 3,338.212
201503 2,204.286 99.621 2,915.772
201506 -4,137.143 100.684 -5,414.738
201509 -10,070.000 100.392 -13,218.114
201512 -13,041.429 99.792 -17,221.251
201603 -7,145.349 100.470 -9,371.785
201606 -9,769.767 101.688 -12,660.506
201609 -6,275.701 101.861 -8,118.790
201612 -6,658.879 101.863 -8,614.358
201703 728.704 102.862 933.539
201706 3,285.955 103.349 4,189.786
201709 2,536.842 104.136 3,210.193
201712 1,750.237 104.011 2,217.452
201803 1,532.159 105.290 1,917.590
201806 1,387.423 106.317 1,719.665
201809 901.535 106.507 1,115.431
201812 576.786 105.998 717.058
201903 31.916 107.251 39.214
201906 49.301 108.070 60.116
201909 83.676 108.329 101.787
201912 -0.053 108.420 -0.064
202003 33.390 108.902 40.404
202006 17.793 108.767 21.557
202009 25.599 109.815 30.718
202012 9.303 109.897 11.155
202103 63.762 111.754 75.186
202106 161.075 114.631 185.166
202109 145.317 115.734 165.459
202112 115.408 117.630 129.288
202203 94.186 121.301 102.320
202206 56.075 125.017 59.107
202209 17.822 125.227 18.754
202212 -22.433 125.222 -23.607
202303 -38.016 127.348 -39.338
202306 -84.157 128.729 -86.149
202309 -42.878 129.860 -43.511
202312 -25.099 129.419 -25.556
202403 -15.970 131.776 -15.970

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Seelos Therapeutics  (FRA:NXE0) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Seelos Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Seelos Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Seelos Therapeutics (FRA:NXE0) Business Description

Traded in Other Exchanges
Address
300 Park Avenue, 2nd Floor, New York, NY, USA, 10022
Seelos Therapeutics Inc is a clinical-stage biotechnology company. The company is focused on developing products that address unmet needs in Central Nervous System (CNS) disorders and other rare disorders.

Seelos Therapeutics (FRA:NXE0) Headlines

No Headlines